Business Context and Reporting Period
This Form 8-K Current Report was filed by Trevi Therapeutics, Inc. on June 18, 2021. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of equity securities. Trevi Therapeutics is an emerging growth company incorporated in Delaware with its principal executive offices in New Haven, Connecticut.
Key Financial Metrics and Transaction Details
The filing details a new equity financing facility rather than reporting standard periodic financial metrics such as revenue or net income.
- Facility Size: Up to $15.0 million in common stock may be sold to Lincoln Park Capital Fund, LLC.
- Commitment Fee: 170,088 shares of common stock issued immediately to Lincoln Park.
- Term: 24-month period commencing upon the effectiveness of the registration statement.
- Share Cap (Exchange Cap): Maximum of 4,175,167 shares (including commitment shares), representing 19.99% of outstanding shares prior to execution.
- Ownership Limit: Lincoln Park cannot acquire more than 9.99% of total outstanding shares at any single point in time.
- Price Floor: No sales permitted if the closing sale price is below $0.50 per share.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Transaction Mechanics
The primary material change is the establishment of an "equity line" with Lincoln Park Capital Fund, LLC. Key mechanics include:
- Discretionary Sales: The Company has the right, but not the obligation, to direct sales. Lincoln Park is obligated to purchase as directed, subject to conditions.
- Daily Purchase Limits:
- Up to 100,000 shares if closing price is $\ge$ $7.50.
- Up to 75,000 shares if closing price is $\ge$ $5.00.
- Up to 50,000 shares if closing price is $<$ $5.00.
- Maximum dollar value per single Regular Purchase is $2,000,000.
- Accelerated Purchases: The Company may direct additional accelerated purchases subject to specific terms.
- Termination: The Company may terminate the agreement at any time without cost or penalty.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the potential sale of shares and the Company's future expectations. Significant risks and contingencies identified include:
- Execution Risk: Uncertainty regarding the Company's ability to satisfy conditions to sell shares to Lincoln Park.
- Operational Risks: Uncertainties regarding product candidate development, clinical trial success, cost, and timing.
- Pandemic Impact: Risks related to the scope and severity of the COVID-19 pandemic on clinical operations.
- Financial Runway: Uncertainties inherent in estimating cash runway and future expenses.
- Going Concern: Risks regarding the Company's ability to continue as a going concern.
- Short Selling: Lincoln Park has covenanted not to engage in short selling or hedging of the Common Stock.
Investor Verification Checklist
- Verify the effectiveness date of the registration statement filed under the Registration Rights Agreement to confirm the start of the 24-month term.
- Monitor the Company's stock price relative to the $0.50 floor price and the tiered daily share limits ($7.50, $5.00 thresholds).
- Review subsequent filings to track the actual volume of shares sold and the total proceeds raised under the Purchase Agreement.
- Check for any stockholder approval if the Company intends to issue shares exceeding the 19.99% Exchange Cap.
- Review the most recent Form 10-Q or 10-K for updated cash runway and liquidity positions, as this 8-K does not provide current balance sheet data.